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ABSTRACT 
 
Multiple Sclerosis (MS) is a chronic inflammatory and demyelinating disease of the central 
nervous system. Susceptibility to develop MS is determined by both genetic and 
environmental factors. The epigenome resides in the interface of genetic and environmental 
factors thereby shaping the transcriptome. Furthermore, epigenetic mechanisms have been 
implicated in the etiology of MS. Epigenetics refers to changes in gene expression that are 
not a result of alterations in DNA sequence. Epigenetic mechanisms include histone 
modifications, DNA methylation and non-coding RNAs. MicroRNAs (miRNAs), small 
non-coding RNAs known to regulate gene expression, have been found dysregulated in 
most diseases, including MS.  
 
This thesis utilizes an animal model of MS, experimental autoimmune encephalomyelitis 
(EAE), to investigate epigenetic mechanisms and miRNAs as mediators and modulators of 
autoimmunity. Through the use of a knockout mouse model we demonstrated that histone 
demethylase Kdm3a is not a ‘master regulator’ of EAE. However, we demonstrated that a 
genetic variant in the rat Kdm3a affects nucleotide secondary structure and potentially 
protein translation. The role of epigenetic mechanisms was demonstrated by the 
identification of parent-of-origin dependent effects (such as genomic imprinting) in the 
inheritance of EAE.  
 
Using next generation sequencing we established a miRNA profile that associates with 
pathogenic immune activation in rat EAE, with potential miRNA-depended regulation of 
several important functions in the development of autoimmunity. Furthermore, by 
investigating the potential of circulating miRNAs as biomarkers of MS, we identified miR-
150 as a putative novel biomarker for MS in the cerebrospinal fluid. 
 
Collectively, we show that modulation of the transcriptome by epigenetic mechanisms and 
miRNAs can explain more of the unknown underlying factors regulating susceptibility to 
autoimmune diseases and that dysregulated miRNAs can serve as markers of ongoing 
pathogenesis. 
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1 INTRODUCTION 
 
The central dogma of molecular biology, first described by Francis Crick in 1958
1
, suggests a 
unidirectional transfer of information whereby deoxyribonucleic acid (DNA)  transcribes into 
ribonucleic acid (RNA), which then translates into proteins. However, it was not long until 
scientists discovered exceptions to this rule, such as viruses using RNAs as templates to make 
DNA
2
, a process now known as reverse transcription. Today we are starting to appreciate the 
complexity of the link between nucleic acids, protein products and phenotype
3
. This thesis 
touches upon a few of the mechanisms whereby epigenetics and microRNAs (miRNAs) can 
modulate and mediate the genetic information in the context of experimental 
neuroinflammation, and how some of these factors can be beneficial in the diagnosis of 
complex diseases such as Multiple Sclerosis (MS). 
 
1.1 Epigenetics  
Conrad Waddington coined the term epigenetics in 1942 in order to explain the process by 
which genes may interact with the environment to produce a phenotype. Epigenetics was later 
redefined by Arthur Riggs in 1996 as the study of ‘mitotically and/or meiotically heritable 
changes in gene function that cannot be explained by changes in DNA sequence
4’. Epigenetic 
changes are presumed to be passed from parent to offspring through the germline and 
retained through consecutive cell divisions. However, epigenetic modifications are very 
flexible in a spatiotemporal manner as they undergo precise and dynamic changes during 
development that contribute to lineage- and cell-specific gene expression patterns
5
. Apart 
from developmental regulation of epigenetic changes there is considerable stochastic 
variation
6-8
, likely mediated by environmental factors. The term epigenetics refers to 
mechanisms underlying phenotype variations such as environmental influences, parent-of-
origin effects, genomic imprinting and X-chromosome inactivation.  Molecularly, epigenetics 
encompasses mechanisms of chromatin and histone modification, large nuclear complexes 
(e.g. polycomb proteins), DNA methylation and non-coding RNAs (ncRNA) (Figure 1).  
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1.1.1 Chromatin and Histone modification  
Fitting roughly 2 meters of double-stranded DNA into the cell nucleus requires efficient 
packaging. This is achieved through the formation of chromatin, where the DNA is wrapped 
around dimers of histone core proteins H2A, H2B, H3 and H4, together with linker histone 
H1, to form the nucleosome
9,10
. Modification of nucleosomal organization can be 
accomplished through variations in histone proteins, chromatin remodeling and post-
translational modification of amino acids in the histone tails. Histone variants have been 
identified for histone H2A and H3 as well as for the linker histone H1, and these result in 
differences of chromatin accessibility and stability
11
. Chromatin remodeling, executed by the 
ATP-dependent chromatin remodeling complex, refers to the repositioning and sliding of 
nucleosomes for subsequent recruitment of transcription factors and transcriptional 
complexes to access the DNA
12
. Post-translational modifications of histone tails include 
acetylation, methylation, phosphorylation, citrullination, sumoylation and ubiquitination. 
Depending on the type of modification and histone tail residue that is modified the end result 
is either transcription activation or repression. For instance, acetylation of histone H3 lysines 
is generally associated with transcriptionally active chromatin
13
, whereas tri-methylation of 
Figure 1: Epigenetic mechanisms. DNA (blue) in the chromosome is organized into chromatin. DNA is tightly 
packed around a core of histone proteins, together forming the nucleosome. Accessibility of the DNA to the 
transcriptional machinery is regulated both by modifications of histone tails (green) and by methylation of 
cytosine bases of the DNA. In addition, non-coding RNAs can regulate chromatin and DNA methylation.    
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H3 lysines residues associates with both transcriptionally competent chromatin (H3K7, 
H3K36 and H3K79) and transcriptionally incompetent chromatin (H3K9 and H3K27)
14,15
. 
The addition and removal of histone marks is mediated by a number of specific enzymes. For 
instance, mono-, di- and tri- methylation of lysine residues is catalyzed by two different 
families of methyltransferases, the SET-domain containing proteins
16
 and DOT1-like 
proteins
17
, respectively, and the removal of methyl-lysine marks is achieved by two families 
of demethylases, the amine oxidases
18
 and jumonji C (JmjC)-domain- containing, iron-
dependent dioxygenases
19
.  
 
1.1.2 DNA methylation   
Methylation of DNA involves covalent addition of a methyl group to cytosine bases by DNA 
methyltransferases (DNMTs). DNMTs recognize cytosine bases of cytosine-guanine di-
nucleotides (CpG). Methylation of CpGs islands, i.e. CpG-rich regions, at transcription start 
sites is usually associated with transcriptional repression as the methyl group blocks the 
binding of transcription factors and complexes of the transcriptional machinery
20
. However, 
genome-wide mapping of methylation has demonstrated the occurrence of DNA methylation 
throughout the genome: in gene bodies, in gene-flanking regions and in intergenic areas
21
, 
thereby introducing a wide array of regulation by DNA methylation within different genetic 
contexts. DNA methylation is an important regulator of gene expression and is therefore a 
central component in numerous cellular processes such as embryonic development, genomic 
imprinting, X-chromosome inactivation and maintenance of chromosome stability
22
. 
 
1.1.2.1 Parent-of-origin effects and Genomic imprinting 
The term parent-of-origin effects refers to the phenomenon in which inheritance of genetic 
variation is dependent on parental transmission, i.e. inheritance from the mother or from the 
father. Parent-of-origin effects may be caused by genomic imprinting, the paternally inherited 
Y-chromosome, the maternally inherited mitochondrial genome and intrauterine effects. The 
extent to which parent-of-origin contributes to the heritability of complex traits is currently 
unknown.  
 
Unequal mono-allelic gene expression, whereby the allele that is transcribed depends on 
parental transmission, is known as genomic imprinting. For example, an imprinted gene that 
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is active on a maternally inherited chromosome will be expressed from the maternal 
chromosome and silent on the paternal chromosome, in both male and female offspring. 
Imprinted genes primarily exist in clusters regulated by imprinting control regions (ICR). The 
ICR is differentially methylated to permit or to silence gene expression
23,24
. An imprinting 
mark is set in the germ cell and is stably inherited, on the same chromosome, during meiosis 
of the embryo and in the adult
25
. However, imprinting can be lost in adulthood and can be 
inconsistent across tissues of the same organism
26
. In addition to methylation of the ICR, long 
ncRNAs (lncRNA) and histone modifications can also provide regulation of mono-allelic 
expression. The underlying biological relevance for genomic imprinting is not clear, but it is 
hypothesized that there is likely a strong selective advantage for the evolution and 
maintenance of this phenomenon. Imprinting is conserved between humans and mice to a 
large extent and the importance of proper imprinting is evident from the observation of 
disturbed development and human disease when imprinting is lost
24,27-29
.   
  
1.1.3 Non-coding RNA 
Coding genes only account for about 1% of the human genome
30
. For a long time the non-
coding genome was believed to be unimportant, it was considered ‘junk DNA’. Thanks to the 
ENCODE project we now know that a broad spectrum of RNA molecules are being 
transcribed, ranging from long protein-coding messenger RNAs (mRNAs) to short non-
coding transcripts
31
. However, compared to coding RNAs, only the functions of a small 
number of the ncRNAs are currently experimentally validated. A known feature of ncRNAs 
is that they can modulate epigenetic states via sequence homology.  lncRNAs are known to 
regulate both genomic imprinting
32
 and X chromosome inactivation
33,
 and the shorter Piwi-
Interacting RNAs (piRNAs) are known to be important for silencing of retrotransposons
34
. 
The most studied class of ncRNAs is the microRNAs (miRNAs), which are the focus of the 
next section of this thesis.  
 
1.2 MicroRNA 
MiRNAs are small (20-23 nucleotides) single-stranded RNA molecules that regulate gene 
expression. They are generally transcribed by polymerase II, using independent promoters, 
into primary miRNA transcripts (pri-miRNAs)
35
. However, there are alternatives whereby 
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Figure 2. MiRNA biogenesis. MiRNAs are transcribed by polymerase II into pri-miRNAs. Drosha 
and DGCR8 process these into pre-miRNA before export, by Exportin-5, to the cytoplasm. In the 
cytoplasm Dicer cleaves pre-miRNA into double-stranded short RNA molecules. One of the strands 
gets incorporated into the RNA-induced silencing complex (RISC) to facilitate binding to target 
mRNA. 
miRNAs are transcribed by polymerase III
36
, as well as miRNAs being transcribed together 
with coding genes, where they are present either in exons, introns or in close genomic 
proximity. MiRNAs encoded in clusters can be transcribed together as well as 
independently
37
. Pri-miRNAs are processed in the nucleus by an endonuclease complex 
comprising of the RNase III enzyme Drosha and the DGCR8 (DiGeorge critical region 8) 
protein, into smaller precursor miRNA (pre-miRNA) hairpin structures. After nuclear 
processing the pre-miRNA is exported to the cytoplasm by Exportin-5 coupled with Ran-
GTP
38,39
. In the cytoplasm the pre-miRNA is cleaved by the endoribonuclease Dicer into a 
short double-stranded RNA molecule. The miRNA-processing factors Dicer, Dgcr8 and 
Drosha are all essential for viability in mice. Knockout mice lacking these key processing 
genes accumulate miRNA precursors and die during early gestation with severe 
developmental defects
40-42
. Following cleavage by Dicer, one of the strands of the miRNA 
duplex is subsequently loaded into the RNA induced silencing complex (RISC), and the other 
is degraded. The mature miRNA together with Argonaute proteins (Ago) of the RISC 
complex targets complementary sites of the target mRNAs. The biogenesis of miRNA is 
illustrated in Figure 2. 
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Interaction of miRNA and mRNA requires base-paring of the miRNA ‘seed’ sequence with 
complementary nucleotides in the 3’ untranslated region (UTR) of the target mRNA43. The 
miRNA seed is composed of nucleotides 2-8 and is the only binding necessary for miRNA to 
exert post-transcriptional regulation of mRNAs. The binding generally results in a reduction 
of protein product, mainly due to mRNA decay but also through translational repression
44,45
. 
However, during certain circumstances miRNAs have also been demonstrated to up-regulate 
translation
46
.  
 
1.2.1 MiRNAs in regulation of the immune system  
The immune system is comprised of two sub-systems termed innate and adaptive. The 
former is the part of the fast-acting and relatively non-specific response against pathogens 
and is mediated by cells such as neutrophils and antigen presenting cells (APCs). The 
adaptive immune system is an acquired and specific response mediated in part by 
lymphocytes. When cells of the immune system encounter inflammatory cues, intracellular 
signals are sent to their nuclei to initiate changes in transcription, resulting in some genes 
being turned on and others being turned off. Similar to protein-coding genes miRNAs are 
also transcriptionally regulated during the immune response. MiRNAs are critical for fine-
tuning immunity
47,48
 and cells of the immune system express unique miRNA profiles 
contributing to their specific functions
49
. Furthermore, miRNAs are important regulators of 
hematopoiesis and lineage-specific cell commitment
50-52
.  
 
A role for individual miRNAs in both innate and adaptive immune response has been 
demonstrated. One of these key miRNAs regulating the immune system is pro-inflammatory 
miR-155. Activation of toll-like receptors (TLR) and the interleukin (IL)-1 receptor induces 
expression of miR-155, which successively negatively regulates TAB2, an important 
molecule of the IL-1 signaling pathway
53
. This creates a negative feedback loop, thereby fine-
tuning the microbial immune response. An opposite mode of action is apparent in viral 
infection as miR-155 has been shown to promote a positive feedback loop stimulating the 
production of type I interferon
54
. MiR-155 is also critical for T band B cell differentiation and 
function
55
, and it is therefore not surprising that miR-155 has been associated with most 
autoimmune disorders including rheumatoid arthritis
56
, systemic lupus erythematosus (SLE)
57
 
and MS
58
.  
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Other central miRNAs in the immune system are miR-146a, miR-181a and miR-150. MiR-
146a was first identified as a negative regulator of NF-κB signaling upon TLR signaling 
through targeting the downstream molecules, tumor necrosis factor (TNF) receptor-associated 
factor 6 (TRAF6) and IL-1 receptor-associated kinase 1 (IRAK1)
59
. It has since then 
continually considered as an important regulator of the innate immune responses, although 
evidence of miR-146a regulating T cell differentiation and activation has also been 
demonstrated 
60,61
. MiR-181a is known to be important for T cell differentiation
50,51,62
  and for 
regulating sensitivity of the T cell receptor
63
. MiR-150 is also a regulator of immune cell 
differentiation
52,64,65
, but has additional roles such as regulation of B cell receptor 
signaling
66,67
.   
 
1.2.2 Circulating miRNAs 
In addition to identification in cells and tissues, miRNAs can also be detected in extracellular 
body fluids including plasma, serum, cerebrospinal fluid (CSF), urine and saliva
68
. They are 
released from cells, actively or passively, in membrane-bound vesicle particles or in protein 
complexes (Figure 3). The vesicles can either be formed inside the cells followed by 
exocytosis out into the extracellular space (exosomes), or by evagination and budding from 
the plasma membrane (microvesicle)
69
 (Figure 3). Various cell types including neuronal cells, 
epithelial cells, immune cells and tumor cells are known to release extracellular miRNAs. 
Furthermore, miRNAs in exosomes have been shown to be transferred to other cells, thereby 
possibly mediating cell-to-cell communication. There are now a few studies demonstrating 
such exosome-transfer of miRNAs between cells of the immune system. For instance, 
exosomes from regulatory T cells containing Let-7d suppress pathogenic T cells
70
. Another 
example is T cell-mediated transfer of miRNAs to dendritic cells (DCs)
71
. The mechanism 
underlying exosome-mediated miRNA transfer and the loading of miRNA in extracellular 
vesicles remains to be elucidated.   
 
During the last couple of years, circulating miRNAs have become a new and promising form 
of biomarker. There are several advantages in using circulating miRNAs instead of 
conventional disease markers, although there are also a few disadvantages (listed in Box 1). 
Circulating miRNAs have been proposed as putative biomarkers for a broad range of 
pathologies including different types of cancers, cardiovascular diseases, diabetes, neuro- 
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Figure 3. Circulating miRNAs. MiRNAs can be released into the circulation encapsulated in 
exosomes or microvesicles, or are protected from nucleases by protein complexes.   
 
 
 
degenerative disorders and autoimmune diseases. In the case of cancers, different bodily 
fluids can be used to address the relevance of miRNAs as biomarkers of the specific type of 
malignancy, and for diseases of the cardiovascular system such as atherosclerosis, myocardial 
infections and stroke, the blood compartment presents the most obvious body fluid to study. 
However, circulating biomarkers in the blood are not so specific and can be a consequence of 
diseases (or organismal conditions) other than that studied. For neurodegenerative diseases 
and other diseases of the CNS, the CSF, lying at the interface between the CNS and blood, 
might better reflect the activities in the target organ. Unlike circulating miRNAs in the blood, 
miRNA biomarkers in the CSF are still in early stages of development, probably due to the 
lower accessibility of CSF compared to blood. However, recent progress in high-throughput 
sequencing of the extremely low levels of circulating miRNAs present in the CSF has proven 
fruitful and will undoubtedly aid in future discoveries of novel miRNA biomarkers
72
.  
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Box 1. Advantages and disadvantages of circulating miRNAs as biomarkers  
Advantages Disadvantages 
High stability in extracellular environments 
A single miRNA may not reflect the complex 
pathogenic events 
Easy detection using qPCR 
Detection of low amounts is technically 
challenging 
Several miRNAs can be analyzed from the 
same isolation procedure 
Data normalization (lack of endogenous 
controls)  
Mirror events of the target organ (CSF) 
miRNAs may be involved in diseases of other 
organs (blood) 
Non-invasive sampling procedure  
 
1.3 Multiple Sclerosis  
MS is a chronic inflammatory and neurodegenerative disease of the CNS first 
comprehensively described by Jean-Martin Charcot in 1868.  MS affects millions of people 
worldwide and in Sweden has a prevalence of 0,2% of the population
73
. It is the major cause 
of non-traumatic neurological disability in young adults with a large associated economic 
burden on society. Onset of disease occurs around 20-40 years of age, with women being 
affected more than twice as often as men
73
. MS associates with a marked reduction in life 
quality of affected patients, with a majority of patients having to end their working career 
prematurely
74
.  
 
MS is characterized by the breakdown of blood brain barrier (BBB) integrity, thereby 
allowing significant infiltration of immune cells into the CNS and subsequent development of 
inflammatory lesions, demyelination and ultimately neuronal degeneration and glial scar 
formation
75
. Symptoms of neurological defects in MS include disturbances of motor function, 
vision, sensation and autonomic systems, all depending on where in the CNS lesions occur. 
However, symptoms relating to disturbances of higher functions, such as various aspects of 
cognition, are also common
76
. Diagnosis of MS, according to the McDonald criteria, requires 
two episodes of demyelinating attacks separated in time and in space
77
. A first event 
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suggestive of MS is called Clinically Isolated Syndrome (CIS). In the most recent update of 
the McDonald
78
 criteria, a second clinical event to confirm a diagnosis of MS, can be 
substituted with evidence of spread in time with magnetic resonance imaging (MRI). The 
procedure for MS diagnosis is primarily executed by examination of medical history and 
neurological symptoms. Measurement of functional states of MS patients is usually 
performed using the expanded disability status scale (EDSS)
79
 and MRI is used to visualize 
presence of inflammatory/demyelinating lesions. Other paraclinical measurements include 
presence of oligoclonal immunoglobulin (Ig) G bands (OCB) and elevated levels of IgG in 
the CSF
80,81
. These two are present in about 70% and 90% of all patients, respectively.  
 
MS has a heterogeneous disease course and clinical presentations. Half of the patients with 
CIS will suffer from a secondary attack of demyelination within two years, and will therefore 
fulfill the criteria for MS and within 20 years over 80% of all CIS patients will develop MS
82
. 
Four main clinical subtypes of MS can be categorized (Figure 4). Most MS patients (80-90%) 
present with the relapsing remitting form of MS (RRMS) which is characterized by recurrent 
episodes of acute neurological destruction (relapses) followed by partial or complete recovery 
(remission). However, most of these patients will later develop a more progressive form of 
MS called secondary progressive MS (SPMS), with accumulating neurological disability. 
About 10% of the patients experience progressive accumulation of disability from disease 
onset, termed primary progressive MS (PPMS)
75
. 
 
 
Figure 4. MS can be divided into four 
subtypes. A majority in diagnosed with 
a relapsing-remitting form of MS 
(RRMS), which in most cases convert 
into a secondary progressive phase 
(SPMS). Some patients displays a 
progressive disease course from onset, 
with or without overlaid relapses; 
primary progressive and progressive-
relapsing MS, respectively. 
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1.3.1 Immunopathology 
Immunologically, MS is considered to be a CD4
+
 T cell-mediated disease, where autoreactive 
T cells are activated in the periphery, through as yet unclear mechanisms 
83
, which result in 
upregulation of adhesion molecules that facilitate migration across the BBB
84
. Once inside 
the CNS the infiltrating autoreactive cells become reactivated upon encounter of their target 
antigen presented by APCs. Following reactivation the effector T cells, infiltrating APCs and 
resident CNS microglia start to produce pro-inflammatory cytokines and chemokines that 
attracts additional immune cells. Although CD4
+
 T cell are considered to mediate disease, 
CD8
+
 T cells are the prominent T cell population within MS lesions
85,86
, and are suggested to 
mediate neuronal damage. The created milieu of immune cells and effector molecules results 
in the destruction of myelin, persistent axonal damage and eventually neurodegeneration
87
.  
 
Although we can only speculate as to the nature of the events initiating MS pathogenesis, 
there is a strong evidence for autoimmune mechanisms, mainly supported by findings in 
animal models of MS. Autoimmunity refers to a break of immune tolerance and the resulting 
immune activation being directed towards self-antigens. The features of MS that support its 
definition as an autoimmune disease are: i) the presence of autoantibodies and autoreactive T 
cells directed towards CNS antigens; ii) infiltration of immune cells into the 
‘immuneprivileged’ CNS; iii) a strong genetic association to the human leukocyte antigen 
(HLA) locus (which is associated with most autoimmune diseases); and iv) an animal model 
can be induced with self-antigens or transfer of autoreactive T cells
88
. However, the presence 
of autoreactive T cells does not have to imply autoimmune disease per se. Autoreactive cells 
are also present in healthy individuals 
89-91
, but are probably kept under control by regulatory 
mechanisms, such as those provided by regulatory T cells (Treg)
92
.  In MS, Tregs have 
reduced suppressive functions, which may further explain the evident breakdown of 
immunological tolerance
93
 
 
There is accumulating evidence for an important role of B cells in MS. These have been 
determined to persist and expand within the CNS and can also be detected in the CSF
94-96
. 
The intrathecal production of IgG and OCB is likely to derive from B cells and plasma 
cells
97
. Elevated levels of chemokines, important for attracting B cells, are used as a marker 
of MS
98,99
 and their levels in the CSF correlate with numbers of CSF cells and levels of 
IgG
100,101
. Furthermore, the therapeutic effect of B cell depleting antibodies (anti-CD20
+
) in 
MS further supports the perception of B cells as mediators of MS pathogenesis
102
.  
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1.3.2 Risk factors of MS 
Although the cause of MS remains unknown, several factors contribute to MS susceptibility. 
The disease is thus thought to arise from a complex interplay between genetic, environmental 
and probably epigenetic factors.  
1.3.2.1 Genetics factors 
MS in a polygenic disease with multiple genes affecting disease susceptibility. The genetic 
component was first demonstrated from studies of familial aggregation
103,104
. In addition, 
studies of MS discordance in twin pairs have highlighted an increased risk in monozygotic 
twins compared to in dizygotic twins
105,106
. Conversely, non-biological siblings do not have 
an increased risk of developing MS if other family members are affected
103
.  
 
The first identified, and still the strongest, genetic risk locus is the region harboring the HLA 
genes on chromosome 6. The strongest association is to the HLA class II allele variant HLA-
DRB1*15:01
107
, which increases MS risk by about 3-fold, whereas the HLA class I gene 
variant HLA-A*02 is associated with a protective effect
108,109
. HLA has been considered for a 
long time as the only reproducible genetic risk factor in MS. Nevertheless, recent technical 
advancements and large international efforts have now identified more than a hundred non-
HLA risk variants
107,110
. Most of these genes are implicated in immune system regulation, 
further supporting a role of inflammation in MS pathogenesis. 
1.3.2.2 Environmental factors 
A growing body of evidence suggests that exposure to environmental factors can influence 
MS etiology. There is a clear latitude gradient, whereby MS risk increases with distance from 
the equator
111,112
. Furthermore, migration studies have demonstrated that re-locating from a 
low-risk area to a high-risk area prior to adolescence results in an acquired risk similar to that 
of the new geographical location
113
. Proposed environmental contributors to this effect 
include influence of the ‘hygiene hypothesis’ and levels of sun exposure. The latter may 
provide direct effects
114
 or may be mediated through levels of vitamin D. Low levels of 
circulating vitamin D have been reported in MS patients and are predicted to affect disease 
activity
115-117
. There is also a seasonal effect, as MS prevalence is lower for children born 
during the autumn compared to those born during spring months
118
.  
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Other environmental risk factors include infection
119
, smoking
120
 and obesity
121
. Smoking has 
further been shown to strongly interact with the main MS HLA risk haplotype, HLA-
DRB1*15:01, and this demonstrates how genetic and environmental factors might interact 
with each other
122
. There are a number of viral infections implicated in MS including herpes 
simplex virus 6 and Epstein Barr virus. The exact role of viruses in contributing to MS 
pathogenesis is still unclear, but mechanisms likely involve molecular mimicry and bystander 
activation
123
. 
1.3.2.3 Epigenetic factors 
A role for epigenetic mechanisms in MS has been previously suggested and is proposed as a 
plausible explanation for some of the ‘missing heritability’ observed in MS. There is a low 
concordance rate for MS in monozygotic twins (maximum 30%)
105,106,124-126
, further 
indicating that non-genetic factors are involved in disease susceptibility. These are most 
likely environmentally-induced epigenetic changes. However, investigation of CD4
+
 T cells 
from three discordant MS twin pairs did not reveal any shared differences in DNA 
methylation and no evidence of genomic or transcriptomic changes that could explain the 
discordance
127
. Other studies have revealed altered epigenetic states in brain tissues of MS 
patients, identifying changes in both DNA methylation
128,129
 and histone acetylation
130
. There 
is also evidence of epigenetic regulation of immune cell function in MS
131-133
. 
 
Parent-of-origin effects have been implicated in MS susceptibility. There is a maternally 
favored transmission of disease, as demonstrated by maternal half-siblings of MS affected 
individuals having an increased risk of developing MS compared to paternal half-siblings
134-
136
. The HLA risk haplotype, which is carried more often by women than men
137
, also 
displays preferential maternal transmission
138
. With the use of whole-genome DNA 
methylation analysis, hypomentylation of several sites in the HLA-DRB1 was associated with 
MS
139
, a finding that could explain the higher expression of DRB1 observed in HLA-
DRB1*15:01 carriers
140
.  
 
1.3.3 MiRNAs in MS 
Study of miRNAs in MS is a relatively new field of research. The first study of miRNAs in 
MS, performed by David Otaegui and colleagues in 2009, analyzed the expression patterns of 
364 miRNAs in peripheral blood mononuclear cells (PBMCs) of MS patients and healthy 
14 
 
controls. Since then, several studies have been conducted, profiling miRNAs in various 
cellular compartments and clinical settings. So far, little overlap in identified and validated 
miRNAs has been observed, further demonstrating the complexity of the disease and the 
intricate regulation performed by miRNAs.  
 
Most of the studies of miRNAs in MS have focused on identifying miRNA dysregulation in 
the immune cell compartment. MiRNAs have been profiled in whole blood, PBMCs, in T cell 
subsets and in B cells
141
. The consensus for all these studies is that there is an altered 
expression of miRNAs during MS and that miRNAs are likely involved in crucial 
inflammatory processes, such as the induction and function of the pathogenic T-cell subsets, 
T helper (Th) 1 and Th17 cells
142-144
. Moreover, MS therapeutics have been reported to 
modulate miRNA expression
145-147
, but whether this is a functional mechanism or a 
secondary consequence of drug treatment requires further investigation.  
 
In addition to the identification of immune regulatory miRNAs in the periphery, studies of 
miRNAs in post-mortem brains have revealed different miRNA expression patterns within 
inflammatory, active and chronic inactive lesions
148,149
. MiRNAs have also been shown to 
negatively affect BBB function in MS
150
. Finally, characterization of miRNAs that are 
important for oligodendrocyte function and differentiation could provide new miRNA-
targeted therapies in order to increase remyelination
151
. The currently hottest area of miRNA 
research in MS is that of circulating miRNAs, either to identify new biomarkers
152-155
 or to 
further understand mechanisms underlying both pathogenic inflammation and the regulation 
of remyelination
156,157
. 
 
1.3.4 Therapeutics 
MS used to be a disease with very limited treatment options, but during the last two decades 
there has been a large increase in development of novel disease-modulating drugs (DMDs). 
These now provide a dynamic range of treatment alternatives, with several novel drugs 
currently at various stages of clinical testing
158
. However, treatments are not yet effective in 
the progressive forms of MS. The first-line of treatment relies on the administration of 
recombinant interferon-beta (IFN-β) through subcutaneous or intramuscular injections. The 
exact mechanisms of action of IFN-β treatment are not fully understood. Although IFN-β 
reduces clinical relapse rate, disease activity and progression
159,160
, it is not effective in about 
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20% of the treated patients, and many treated individuals develop neutralizing antibodies to 
the cytokine
159
. Second- and third-line therapeutics include Natalizumab (Tysabi), and 
Fingolimod. Natalizumab is a humanized monoclonal antibody that binds to the α4-integrin 
of very late antigen-4 (VLA-4), a surface marker present on immune cells, hindering them 
from migrating across the BBB
161
. Natalizumab reduces both relapses and lesions
162,163
. 
However, this treatment is associated with an increased the risk of developing progressive 
multifocal leukoencephalopathy (PML), a serious and potentially lethal brain infection caused 
by the JC virus
164
. Fingolimod is one of the newest drugs on the market and the first oral 
drug. It targets sphingosine-1-phosphate receptors and results in reduced number of T 
lymphocytes in the peripheral circulation
165
. A common aspect of current DMDs is that they 
do not halt disease, repair tissue damage or revert disease progression, and thus are limited to 
reducing the disease activity.  
 
1.3.5 Biomarkers of MS 
Given the complexity of MS there is a great need for biomarkers in order to capture different 
aspects of disease heterogeneity. The establishment of good biomarkers may provide a better 
understanding of disease etiology, facilitate diagnosis, permit estimate of disease activity, 
permit prognosis prediction, and evaluate treatment response. While the field of biomarker 
discovery is highly active in MS, few of the prospective markers make it into clinical 
practice. Those that are routinely used in the clinic are the previously mentioned diagnostic 
markers, IgG and OCBs
80,81
 as well as measurement of neutralizing antibodies to the common 
MS treatments (recombinant IFN-β and Natalizumab). High titers of neutralizing antibodies 
to recombinant IFN-β treatment result in reduced therapeutic efficacy as the antibodies bind 
to the IFN-β receptor and thereby block expression of interferon-stimulated genes166,167. 
Conversely, antibodies to Natalizumab are only developed in a few percent of treated 
patients
168
, but can, in addition to reducing treatment efficacy, also result in humoral-
mediated (infusion-related) adverse side-effects
169
.  
 
Several other molecules that can be measured in the CSF have been validated as biomarkers 
of disease activity in MS. Some correlate with immune activity while others relate to ongoing 
axonal injury. An example of the latter is neurofilament-light chain (NFL), which is released 
into the CSF upon neuronal damage and their levels are elevated in the CSF of MS patients, 
especially during clinical relapses
170,171
. Inflammatory mediators include chemokine (C-X-C 
16 
 
motif) ligand 13 (CXCL13) and metalloproteinase 9 (MMP9). CXCL13 is a chemokine that 
binds to its corresponding receptor present on B cells. Levels of CXCL13 are increased in the 
CSF of MS patients
98,99
, correlate with an unfavorable disease prognosis of RRMS
172
, and 
further predict conversion of CIS patients to definite MS
173
. MMP9 is also elevated in the 
CSF of MS patients
174
. It is expressed by activated leukocytes to modulate the extracellular 
matrix, thereby facilitating entry to the CNS, but can also directly contribute to myelin 
damage
175
. None of these markers can alone be used to diagnose and monitor disease. Instead 
it has become evident that a larger profile of markers is necessary to serve this purpose.  
  
1.4 Experimental Autoimmune Encephalomyelitis 
Animal models are widely used to study inheritance, disease transmission and the underlying 
disease mechanisms of complex diseases such as MS. Animal models provide a system with 
minimized genetic heterogeneity, controlled environmental conditions and a relatively 
unlimited sample size. Induction of disease also allows for investigation of initial events prior 
to disease onset, a time-point that cannot be studied in human MS. Furthermore, the use of 
animal models provides access to all types of cells and tissues, including the CNS. This is 
crucial as the CNS is difficult to access in human disease, and immune responses in this 
tissue are difficult to monitor. Although identified genes may not be identical in rodents and 
humans they may give insight into dysregulated functions and pathways important for disease 
development and activity
107,176
. Various techniques aimed at modifying the genome have also 
provided systems to study the effects of specific genes in isolation.  
 
Experimental Autoimmune Encephalomyelitis (EAE) is the most widely used animal model 
to study MS-like disease. In has proven extremely valuable for understanding of fundamental 
(neuro) immunological processes as well as adaptive inflammatory responses in general. EAE 
can be induced in multiple rodent species, but also in non-human primates. Disease induction 
is either active, using whole spinal cord homogenate, purified myelin, myelin proteins or 
peptides thereof, or passive through adoptive transfer of T cells reactive against CNS 
antigens. In addition, EAE develops spontaneously in a mouse model with genetically-
engineered, myelin-specific T and B cells. Depending on species and induction protocols, 
different disease courses and pathologies can be modelled.  
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Figure 5. MOG-EAE in susceptible 
DA rats and resistant PVG rats. 
Animals are scored based on their 
accumulation of motor deficits. 
Onset of disease is usually around 
day 10. 
 
 
1.4.1 MOG-EAE  
Myelin oligodendrocyte glycoprotein (MOG)-EAE can be induced both in mice and in 
rats
177
. In the C57BL/6 mouse model mice are injected with MOG35-55 peptide or recombinant 
MOG, in emulsion with complete Freund’s adjuvant containing Mycobacterium tuberculosis. 
The mice are also co-injected with pertussis toxin to further induce BBB permeability and to 
skew T effector cells to a pathogenic Th17 response
178,179
. This induction protocol results in a 
chronic form of EAE. We use mouse models of EAE to establish a role of specific targeted 
genes in the context of inflammation in general, and neuroinflammation in particular. 
 
In the study of heritability of neuroinflammation and in order to identify miRNAs regulating 
disease we have employed a rat model of EAE. In rats, EAE is induced with recombinant 
MOG together with incomplete Freund’s adjuvant (without Mycobacterium) and without 
pertussis toxin. In susceptible rats this induction protocol results in a chronic relapsing-
remitting form of EAE, mimicking that of human MS
180
. We have used different inbred rat 
strains with varying susceptibility to MOG-EAE to identify genetic loci that regulate clinical 
EAE phenotypes and to further characterize functional implications of these responses. The 
two strains used in the studies are the EAE-susceptible Dark Agouti (DA) rat strain and the 
major histocompatibility complex (MHC) identical Piebald Virol Glaxo (PVG) rat strain that 
is resistant to the same immunization protocol (Figure 5). Following immunization both 
strains mount an immune response in the secondary lymphoid organs, but only in DA rats 
does the activation to the myelin antigen progress become pathogenic in nature. Onset of 
disease is around day 10-12 post-immunization, which corresponds to the initiation of 
demyelination in the CNS.   
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Assessment of MOG-EAE is the same for both mice and rats. It consists of daily 
measurements of weight loss and visual inspection of clinical symptoms. The animals suffer 
from ascending paralysis beginning with paralysis of the tail. The symptoms are scored based 
on the following scale: 0 = no sign of disease, 1 = loss of tail tonus, 2 = hind limp paraparesis, 
3 = hind limb paralysis, 4 = tetraplegia and 5 = death.  Similarly to MS, the disease symptoms 
reflect the location of the lesions in the CNS.  However, as opposed to MS, in which the 
majority of the lesions are found in the brain, EAE primarily affects the spinal cord in these 
rats and the C57BL/6 mouse model.                       
 
1.4.2 EAE and the immune system 
Like MS, EAE is described as a T cell-mediated disease. With the use of different EAE 
models several key immunological mechanisms of MS pathogenesis have been revealed. 
IFN-γ-producing Th1 cells were long thought to be the CD4+ effector cells in EAE181. It was 
subsequently discovered that IL-23 was required for EAE induction
182
. This led to the 
identification of IL-23-induced Th17 cells that produce IL-17 as their major effector 
cytokine. This novel CD4 T cell subset has also been detected in MS, and have been the 
subject of several studies in MS and in EAE
183
. Both Th1 and Th17 cells can induce EAE
184
; 
however, neither of the effector cytokines is absolutely required for disease development in 
EAE
185,186
, indicating that they have redundant functions in disease initiation. Furthermore, 
EAE was used to establish the role of regulatory T 
187
 and B cells
188
 in regulating 
autoimmune responses. 
 
1.4.3 Genetic regulation of EAE 
MS and EAE share many similarities when it comes to genetic regulation. They are both 
polygenic diseases, with the MHC locus (analog to the human HLA locus) as the major 
genetic risk factor
189
 and an overlap of identified non-HLA genes
190
. In addition to the MHC 
locus, over 50 quantitative trait loci (QTL) have been identified to regulate EAE in rats and 
mice
191
. The identified QTLs harbor numerous genes and positional cloning of these has 
proven difficult and time consuming. Through continuous efforts in isolating congenic 
fragments and the use of gene targeting in mice we have been able to pinpoint some of 
 19 
 
specific genes responsible for the observed phenotypes. Identified genes in both EAE and MS 
include the MHC class II transactivator (Ciita)
192,193
 and IL22RA2
110,194,195
 and Vav1
196
 .   
 
1.4.4 MicroRNAs in EAE 
The first evidence of an importance of miRNAs in EAE arose from the laboratory of 
Professor Pei in 2009, showing that miR-326 regulates differentiation of Th17 cells in vitro 
an in vivo through targeting of Ets1
197
. The differential expression and the regulatory function 
of miR-326 have been demonstrated in both MS and EAE. Since then several studies have 
defined a role for miRNAs in EAE pathogenesis, mainly as regulators of pathogenic Th1 and 
Th17 cells and the pro-inflammatory cytokines they produce
58,198-200
. A special interest has 
focused on the role played by miR-155. MiR-155 is a miRNA known to be important for the 
immune system
201,202
 and it has been shown to be vital to EAE pathogenesis, as demonstrated 
by knock-out of miR-155 which results in markedly reduced EAE attributed to the role of 
miR-155 in regulating Th1 and Th17 responses
203,204
. EAE experiments have also shown the 
importance of miR-124 in microglia activation. Ponomarev et al showed that by increasing 
the levels of mR-124 they could switch microglia from an activated to a quiescent state and 
thereby inhibit onset of EAE
205
. Additionally, investigation of miRNA profiles of active 
lesions of primate and mouse EAE demonstrated high overlap in expression patterns
206
, 
further indicating conservation of miRNA function in neuroinflammatory processes.  
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2 THESIS AIMS 
 
The overall goal of this thesis was to investigate the contribution of genetic and epigenetic 
factors on gene regulation in the context of autoimmune neuroinflammation with the long-
term goal to understand underlying mechanisms and to facilitate disease diagnosis.  
 
The specific scientific goals for each study were: 
 
Study I:  to test the hypothesis that genetic variation in an enzyme that controls the 
epigenome and has a broad impact on transcription can affect immune system 
functions and susceptibility to autoimmunity. 
 
Study II:  to assess if there is an impact of epigenetic mechanisms on inheritance of 
autoimmunity.  
 
Study III:  to establish if miRNA-mediated pathways can lead to susceptibility to 
autoimmunity.  
 
Study IV:  to investigate the potential of using circulating miRNA as biomarkers in MS.  
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3 METHODOLOGICAL CONSIDERATIONS 
 
This thesis comprises a variety of materials and methods, all of which are described in detail 
in the included studies. Here I would like to take the opportunity to review some of the 
methodologies more thoroughly.   
 
3.1 The era of the “Omics” 
Technical advancements during the last decades have given rise to the era of ‘-omics’, e.g. 
genomics, epigenomics and transcriptomics to name a few. Genomics refers to the study of 
entire genomes, including sequence and structure, epigenomics to the study of the 
epigenome, i.e. the complete set of epigenetic modifications of a cell or a tissue, be it histone 
modifications or DNA methylation, and transcriptomics to the study of the transcriptome 
reflected by all transcribed RNAs. Studies in this thesis include methods to investigate the 
respective contributions of genomics, epigenomics and transcriptomics in the regulation of 
neuroinflammation.   
 
3.1.1 A genomic approach to identify epigenetically regulated disease- 
predisposing QTLs 
The influence of epigenetic mechanisms (more specifically mechanisms that confer parent-
of-origin effects) on predisposition to develop autoimmunity was investigated using genome-
wide linkage analysis in rats (Study II). To enable mapping of the parental origin of disease-
predisposing alleles we employed a reciprocal backcross breeding strategy of DA and PVG 
(Figure 6). In the DA backcross, (DAxPVG)xDA, DA mothers were bred with F1 fathers to 
create DAxF1, and F1 mothers were bred with DA fathers to create F1xDA. This result in 
PVG alleles that can be either exclusively paternally inherited (DAxF1) or exclusively 
maternally inherited (F1xDA). The same reciprocal breeding was performed for the PVG 
backcross, (DAxPVG)xPVG. This strategy creates a large cohort of genetically unique 
backcross animals of varying susceptibility to EAE, which enables genome‐wide 
identification of genomic regions that are inherited together with disease. We identified 
different inherited alleles from the parental strains using microsatellite markers of di- or tri-
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nucleotide repeats, where the number of repeats differs between the two strains. The objective 
of linkage mapping is to define markers that are linked to the measured phenotype in order to 
define QTLs regulating disease.  
 
 
 
 
 
 
 
 
Employing a genome-wide approach enables simultaneous identification of all QTLs 
regulating the phenotype of interest. Linkage mapping is a fairly cost-effective and feasible 
way to identify all genomic regions underlying complex traits. However, QTLs are usually 
quite large and thus contain multiple genes, and further dissection of the QTLs is necessary to 
pinpoint the actual genetic variation that is responsible for the observed effect.  
 
While using microsatellite markers to map the origin of the alleles is convenient and 
informative, we now have access to the sequenced genomes of DA and PVG rats
207
.  This 
enables identification of all single nucleotide polymorphisms (SNPs) segregating between the 
two strains. As the bi-allelic SNPs occur with higher density in the genome they can be 
exploited to investigate genetic variations underlying QTLs. Using polymerase chain reaction 
(PCR) amplification and sequencing of SNPs in F1 hybrid animals we can investigate allele-
specific expression and thereby identify imprinted genes. However, this approach has its 
limitations: i) SNPs are not present in all genes; ii) low sequence coverage can result in 
inaccurate SNP calling; iii) the gene must be expressed in the investigated tissue or cell-type; 
iv) the SNPs have to be present in the processed mRNA. Intronic SNPs could potentially be 
detected in unspliced transcripts, but if they are present they are detected at very low levels. 
We attempted to identify allele-specific expression of candidate genes underlying identified 
parent-of-origin loci, but we had very limited success due to the above-mentioned limitations.  
Figure 6: Schematic illustration 
of the reciprocal backcross 
design used to identify parent-
of-origin dependent risk loci in 
Study II.  
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3.1.2 Transcriptomics 
While the term transcriptome refers to the complete set of RNA molecules expressed by an 
organism, the term is more widely used to describe an array of RNA transcripts produced in a 
particular cell or tissue at a specific time-point. In contrast to the genome, which is 
characterized by stability, the transcriptome changes actively due to internal and external 
signals. Only about a decade ago the analysis of the transcriptome was restricted to the use of 
microarrays with a predetermined number of detectable transcripts. However, with the rapid 
technical advancement of massive parallel sequencing
208,209
 and the development of 
bioinformatics tools to analyze the sequencing output, this situation has changed 
dramatically. The introduction of next-generation sequencing (NGS) not only provided 
whole-genome sequences, such as the case for our two rat strains of focus, DA and PVG
207
, 
but also the complete transcriptome of cells and tissues. As both the costs and time of 
sequencing continues to decrease, NGS is becoming an increasingly attractive option for 
transcription studies. NGS is now widely used in most aspects of RNA biology, with 
applications such as identification and quantification of both rare and common transcripts, 
analysis of splice junctions, detection of isoforms, novel transcripts and gene fusions, and 
detection of long and short non-coding RNAs.  
 
In Study III we used NGS to detect and quantify all small RNAs present in the lymph nodes 
of DA and PVG. Small RNA sequencing allows detection of 17-35nt long RNA sequences 
and the sequence output is subsequently mapped to known miRNA of the miRBase 
repository
210
. In addition to all known miRNAs, NGS also allows for identification of novel 
miRNAs and other small non-coding RNAs. This is a clear advantage of NGS over 
microarray-based detection methods (such as the previously published affymetrix array
211
 
utilized in studies I and III) and methods using pre-spotted PCR plates and PCR-microfluid 
cards where predefined sets of probes and primers limit the detection possibility. Conversely, 
the latter produces a user-friendly output, which compared to NGS does not require 
bioinformatics expertise in data handling. In Study IV we used TaqMan low-density arrays 
(TLDA), a microfluid based system, to profile circulating miRNAs in the CSF. There TLDA 
cards have an advantage over NGS due to a requirement of far less input material, even 
though recent publications indicate that these ultra-low amounts of RNA can be 
sequenced
72,212
. Although not providing full small-RNA coverage the TLDA cards provided a 
decent level of detection, with 754 detectable miRNAs, in just a few hours, all in a 
straightforward analysis format.  
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3.1.3 Using bioinformatics tools to decipher large data sets  
The use of large-scale ‘omics’ experiments has introduced a need for bioinformatics tools to 
interpret data and to generate information on possible functionality. A multitude of databases 
has been developed to serve as repositories for diverse biological information such a basic 
nucleotide sequences (GeneBank)
213
, genomes (Ensembl)
214
, RNA families (RFam)
215
, 
miRNAs (miRBase)
210
 and proteins (UniProt)
216
, but also for more special areas. Databases 
of known and predicted imprinted genes in humans and mice were used in Study II to predict 
possible genes underlying our identified parent-of-origin dependent QTLs. Several 
bioinformatics tools were utilized in Study III to identify miRNAs and miRNA-regulated 
functions and pathways. To identify the miRNAs detected in lymph nodes of DA and PVG 
rats we subjected all filtered sequences to the miRanalyzer online tool
217
 which maps the 
sequenced reads to known miRNAs annotated in the miRBase registry. In addition, 
miRanalyzer also predicts novel miRNAs, a feature especially important for (mammalian) 
species other than human and mouse, in which fewer miRNAs are annotated (2558 human 
and 1915 mouse mature miRNAs compared to 765 mature miRNAs in the rat (miRBase 
v21)). As functional annotations of miRNA target genes are still in its infancy, numerous 
online computational tools have been developed to predict targets of known miRNAs based 
on seed sequence complementarity, sequence conservation, thermal stability of the 
miRNA/mRNA duplex and other parameters
218
. Each tool has its own algorithm and predicts 
slightly different, although to some degree overlapping, sets of target genes. With this in 
mind we chose to only consider overlapping targets predicted by two well-known target 
predictions tools, TargetScan
43
 and miRanda
219
, to predict targets of differentially expressed 
miRNAs in rats. Despite overlooking some targets this improves the chance of identifying 
true target mRNAs. In order to interpret functionality and to reduce the complexity of 
differentially expressed gene sets they have to be put into context. Pathway analysis achieves 
this by integrating knowledge databases of biological processes in which genes and proteins 
are known to be involved, but also of where and how proteins interact with each other. 
Several tools, such as Ingenuity Pathway Analysis (www.qiagen.com/ingenuity) which has 
been used in Study III, have been developed to facilitate this integration and to indicate 
downstream consequences of gene dysregulation. However, the classification of biological 
function and interactions is based on annotations, and so is restricted to what is known
220
. 
Furthermore, pathway analysis cannot display the dynamic nature of a biological system. 
Although there are limitations, the output of pathways and functions enriched in the data set 
enable biologists to focus on further relevant investigations.  
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3.2 Methods for RNA detection and quantification  
 In this thesis investigation of expression levels for individual transcripts relied on 
quantitative real-time polymerase chain reaction (qPCR), using either SYBR green or 
TaqMan-based methods. qPCR is a widely used and fairly simple florescence-based method 
that can measure small amounts of nucleic acids rather quickly and with relatively high 
sensitivity and specificity
221
. The latter is determined by the primers (SYBR) or by both 
primers and a probe (TaqMan). Although there are many advantages of qPCR, such as being 
robust and reproducible, there are disadvantages and limitations. qPCR is a highly sensitive 
method and it is therefore important to scrutinize all parameters of the qPCR reaction before 
making assumptions about gene expression. However, in Study I we demonstrate that 
although failed PCR amplifications cannot provide information on gene expression, it can 
help to discover interesting underlying biology, such as the implications of altered RNA 
secondary structure on protein translation. 
 
Although miRNA profiling is beneficial to achieve an overview of the presence and 
regulation of miRNAs, findings of differential expression need to be confirmed with miRNA-
specific methods in order to determine their accuracy. In Studies III and IV we used TaqMan 
miRNA assays to confirm and quantify mature miRNA levels. The short sequence length of 
mature miRNAs (approximately 22nt) and the fact that the mature miRNA sequence is also 
present in the pri- and pre-miRNA transcripts presented new challenges to qPCR technology. 
A couple of methods have since then been developed to circumvent this problem, all with the 
approach to add nucleotides to extend the miRNA length
222
. The extension is most commonly 
produced either by addition of a poly A tail
223
 or, in the case of TaqMan microRNA assays by 
addition of a stem loop
224
, to the 3’ end during the RT reaction (Figure 7). The TaqMan stem 
loop not only adds sequence length to the miRNA but also increases assay specificity by 
having a short single-stranded region that is complementary to the miRNA 3’end. The stem 
loop also improves the stability of the miRNA-DNA heteroduplex, thereby increasing the 
efficiency during the RT reaction
225
. For initial validation of the NGS results (Study III), most 
of the available methods for miRNAs quantification were evaluated. Although methods using 
polyA tailing (and universal reverse primer) are both time efficient and less expensive, 
TaqMan provided by far the most reliable results and was therefore used in all later 
experiments. In order to detect the ultra-low levels of miRNAs present in biofluids such as 
CSF, an additional pre-amplification step has to be introduced.  
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Figure 7: TaqMan miRNA assays add a miRNAspecific stem loop during RT reaction and utilize 
miRNA-specific forward primers and probe during real-time PCR.  
 
 
 
The most common way to normalize gene expression levels to the cellular RNA content is to 
compare the expression levels to an endogenous control RNA, i.e. a housekeeping gene. This 
approach was used in Studies I-III. The key characteristic of a housekeeping gene is that its 
expression does not change depending on experimental conditions and all housekeeping 
genes should therefore be tested accordingly. In the case of exogenous miRNAs in the 
circulation this method of normalization is not applicable, as the individual levels of miRNAs 
and other small ncRNAs in the circulation may not reflect the levels of the transcripts in the 
cells. Instead other methods of normalizing miRNA levels between samples have to be used. 
The most common method is to spike the samples prior to RNA isolation with one or more 
synthetic miRNAs that are absent in the studied species
226
, e.g. C. elegans or Arabidopsis 
thaliana (Study IV). The spike-in oligo is introduced after addition of a lysing solution that 
inhibits the activity of nucleases in the biological sample.  Expression levels of the spike-in is 
used as control in the ΔΔCt method227 and thus compensates for variability during RNA 
extraction and downstream detection procedures. Other normalization methods involve 
normalization to an abundant and least variable circulating miRNA
228
, or in case of large 
number of miRNAs to the average of all detected miRNAs
229
. In Study IV we also investigate 
the potential of using ‘miRNA pairs’230,231, i.e. the ratio of two miRNAs, as a way to 
discriminate patients from controls. This could be a very promising method when we are not 
necessary interested in measuring levels of specific miRNAs but rather deriving a biomarker 
that is a composite of several miRNAs.  
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3.3 Establishing functions and relationships in vitro and in vivo 
Large-scale genomics and transcriptomics provide insight into the regulation that might occur 
during pathogenesis. However, correlation does not imply causality. Consequently a 
causative relationship must be established using in vitro and/or in vivo models. Such is the 
case for miRNA-mRNA interactions (Study III). As predictions of miRNA targets is based 
on computational algorithms, a direct binding of the miRNA to the mRNA 3’UTR should be 
established. This is commonly performed using Luciferase reporter systems where the 3’UTR 
sequence is coupled to Luciferase in a vector system. By co-transfecting the cells with the 
Luciferase vector and the miRNA mimics, binding of miRNA and subsequent loss of target 
gene expression can be measured as absent Luciferase activity. By mutating the miRNA 
binding site in the UTR, the direct binding will be disrupted and Luciferase will be produced 
(Figure 8). This Luciferase-based approach was also used to access the effect of the Kdm3a 
SNP on protein translation. By coupling sequences with either of the two SNP versions to 
Renilla Luciferase we could measure the translation efficiency of the SNPs, simply be 
measuring the levels of light emitted. 
 
To evaluate plausible candidate genes underlying identified QTLs we have adapted both 
knockout and transgenic mouse models. In Study I we utilize a murine knockout of Kdm3a to 
study its role as regulator of the immune system and in Study II we use a transgenic mouse in 
which the Dlk1 gene is overexpressed. Gene targeting in vivo provides a great tool to study a 
gene in isolation, both in disease models and cellular assays ex vivo. Both models modulate 
levels of the gene of interest in all cells. This is advantageous as all cells can be studied for 
the role of the gene of interest in an ex vivo setting. However, complete knockout can be 
lethal, or could potentially result in initiation of compensatory mechanisms. This problem can 
be overcome by using conditional knockout/knock-in models, where the gene of interest is 
only deleted or introduced in specific cell types. Furthermore, genetic alteration can be 
induced at selected time points either during development or in adulthood. This is particularly 
important for genes involved in developmental processes and enables the mouse to develop 
normally before ablation of the gene of interest.  
 
Traditional gene targeting is performed using homologous recombination in embryonic stem 
cells. Although it revolutionized our ways of studying gene function, this technique is both 
slow and expensive. Creating a single mutant mouse can take 2-3 years. Recently, new 
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methods of gene targeting have been developed to provide faster, cheaper and more efficient 
alternatives, such as the zinc finger proteins (ZNF) and the transcription activator-like 
effector nucleases (TALENs)
232,233
. These are genetically engineered sequence-specific DNA 
binding domains that are fused to a non-specific DNA cleavage module. The latest technique 
of genome editing is the CRISPR/Cas9 system. The system, which was originally discovered 
as a bacterial defense to recognize and eliminate foreign DNA, is based on the Cas 
endonuclease that is directed to cleave a specific target sequence using a guide RNA
234
. The 
benefits of these novel techniques are that they facilitate relatively fast and cost-effective 
genetic engineering in potentially all species, including rats. Moreover, in the case of the 
CRISPR/Cas9 method, the target design is fairly simple and multiple mutations can be 
introduced at the same time
235
. The limitations of theses novel methods are the potential off-
target effects in similar but not identical sites and that cellular mosaics can occur. 
 
MiRNA levels in vivo can be altered either long-term using genetically modified animals or 
through transfection using viral constructs, or short-term using miRNA mimics and 
inhibitors. MiRNA manipulation in vivo is not part of this thesis but presents ways to study 
functions of miRNAs in developmental systems, physiological processes and in disease.  
 
 
Figure 8. A Luciferase reporter system can be used to determine direct binding of miRNA to target 
3’UTR. Adequate binding of the miRNA to its binding sites will cause RNA degradation or 
translational inhibition resulting in absent light emission. However, when the binding sites are 
mutated the product gets translated, causing light emission. 
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4 RESULTS 
 
The work presented in this thesis covers multiple areas of genetic, epigenetic and miRNA 
regulation of transcripts important for disease susceptibility and progression as well as the 
application of miRNAs as markers of disease.  
 
4.1 Study I – Genetic regulation of an epigenetic mediator in EAE 
Several previous studies have identified a QTL on rat chromosome 4 that regulates 
susceptibility to a variety of immune-mediated diseases
236-238
, including EAE
239
, but also 
TNF production by macrophages and multiple immune-associated genes
240
. By re-analyzing 
linkage using the latest rat genome assembly, we identified 15 known genes within the 
confidence interval of this QTL (Study I). Given the associated phenotype, we hypothesized 
that histone demethylase Kdm3a would be likely candidate gene due to its role in epigenetic 
regulation that could explain the regulation of expression of multiple immunological genes.  
 
To investigate the hypothesis that Kdm3a is a master regulator of EAE pathogenesis we used 
a Kdm3a knockout mouse. Deletion of Kdm3a in mice had no effect on a number of cell 
subsets or activation of lymphocytes, macrophages and DCs, either at naïve state or during 
EAE. Consequently, it was not surprising that Kdm3a had no effect on EAE susceptibility or 
severity (Figure 9).  
 
 
Figure 9: Kdm3a has no effect of 
EAE susceptibility or severity  
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4.1.1 Implication of SNPs on nucleic acid secondary structure  
Although we recognized that conventional deletion of Kdm3a did not regulate mouse EAE, 
we could not rule out the possibility that natural variations in Kdm3a could contribute to 
immune regulation and EAE in rats. We demonstrated the impact that silent genetic variation 
can have on the RNA structure. We observed that one of the synonymous SNPs in rat exon 
15 of Kdm3a caused problems with RNA amplification in the DA strain. The difference, 
detected using qPCR, was not observed for other exons of the Kdm3a gene (Figure 10A). 
After establishing that this observation was not a result of primer annealing issues due to 
SNPs or alternative splicing, we identified a reduced amplification potential of the DA 
amplicon, where the PCR efficiency dropped 35% compared to PVG (Figure 10B).   
 
 
 
Performing bioinformatics analysis looking at minimum free energy we detected differences 
in complementary DNA (cDNA) secondary structure, which in the DA competes with primer 
annealing. Using computational modeling of RNA shapes we could determine that the SNP 
had a significant potential to affect RNA folding. Examination of protein translation potential 
revealed a possible effect of the SNP on translation efficiency. Taken together, our data 
indicate that synonymous SNPs can have drastic effects on amplification efficiency (with a 
potential to impact levels of protein translation) due to alterations in secondary structure, 
making it important to consider seemingly ‘silent’ genetic variations.  
 
Figure 10: A) Quantitative PCR of Kdm3a exons show drastic amplification differences in DA only for the 
primers surrounding the SNP in exon 15. B) The DA containing SNP sequence amplifies with higher Ct 
values and with lower PCR efficiency than the PVG containing SNP sequence.  
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4.2 Study II - Contribution of parent-of-origin effects in EAE 
Besides the well-documented (straightforward) genetic contribution to EAE, another level of 
genetic and epigenetic regulation speculated to be involved in EAE etiology concerns parent-
of-origin effects. Parent-of-origin effects have been observed in MS in which a preferred 
maternal inheritance of the disease is demonstrated
134-136
, although less is known about 
parental transmission in the context of EAE. Factors contributing to parent-of-origin effects 
include genomic imprinting, Y-chromosome effects and mitochondria. In order to 
unambiguously address the contribution of such effects in EAE, we employed a strategy 
using two reciprocal backcross. The reciprocal backcross design enabled identification of 
parent‐of‐origin dependent regions that regulate susceptibility to EAE. Using this strategy we 
observed that at least one in three of all identified disease-predisposing loci depended on 
parental transmission, with a majority of the identified parent-of-origin QTLs being 
maternally inherited. Our breeding design also allowed us to investigate the influence of the 
paternally inherited Y chromosome and the maternally inherited mitochondria. We found that 
the males that inherited the Y chromosome from the DA developed more severe EAE than 
those males that inherited their Y chromosome from PVG. As opposed to the Y chromosome, 
we did not detect differences between rats with varying mitochondria.  
 
The maternally transmitted disease-predisposing alleles were discovered on chromosomes 1, 
2, 4, 5, 14 and 18. One example of such a QTL is the on chromosome 4 for which the 
maternal DA allele conferred earlier onset of EAE in the F1xDA and F1xPVG rats, but not in 
DAxF1 and PVGxF1. In contrast, the paternally inherited PVG allele at the QTL on 
chromosome 6 conferred more severe EAE in DAxF1 and PVGxF1 animals, but not in 
F1xDA and F1xPVG (figure 11A and B, respectively). Such paternally transmitted disease-
predisposing QTLs were found on chromosome 6, 7 and 10. This pattern of parent-of-origin 
dependent transmission indicates underlying genomic imprinting. Several of the parent-of-
origin dependent QTLs, both maternal and paternal, overlap with previously established 
imprinted genes identified in human and mouse. The paternally transmitted EAE QTL on 
chromosome 6, overlaps with a well-known cluster of imprinted genes, the Dlk1-Dio3 cluster 
which has been implicated in embryogenesis and cancer
241,242
, but has also been found to be 
associated to type I diabetes
243
. In addition to previously established imprinted genes, we also 
attempted to identify novel imprinted genes underlying the parent-of-origin dependent QTLs. 
As previously discussed, we used the complete genome sequence of DA and PVG to find 
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SNPs that could facilitate investigation of allele specific expression
207
. However, despite 
large efforts we were unable to conclusively demonstrate allele-specific expression.  
 
 
Even though there were no coding SNPs between DA and PVG in the genes of the Dlk-Dio3 
cluster to establish allele-specific expression we decided to investigate the region for potential 
genomic imprinting. We found ~50% methylation at a putative ICR in spleen, which 
concords with imprinting status. By investigating the expression levels of the three known 
paternally expressed genes, Dlk1, Rtl1 and Dio3 we found that the PVG allele predisposed for 
lower levels of Dlk1. The Rlt1 and the Dio3 genes conversely did not show any expression 
differences depending on parental transmission. To further explore the role of Dlk1 in EAE 
we used a transgenic mouse overexpressing Dlk1. The lower expression of Dlk1 in the 
wildtype controls resulted in a more severe EAE score (Figure 12), similar to what was 
observed when Dlk1 was paternally inherited from the PVG. Characterization of the Dlk1 
transgenic mouse demonstrated a lower frequency of activated CD4
+
 T cells and B cells 
compared to littermate controls and we observed less IFN-γ producing Th1 cells in the Dlk1 
transgenic mice when differentiating naïve CD4
+
 T cells into different effector subsets in 
vitro. Taken together this study demonstrates a role of the imprinted Dlk1 gene on the 
adaptive immune response in EAE. 
 
Apart from coding genes the Dlk1-Dio3 locus contains a large cluster of more than 50 
miRNA genes, all of which are maternally expressed
241
. Similarly, some of these miRNAs 
were also determined to be differently expressed between DA and PVG during EAE immune 
Figure 11: Paternal transmission of-disease predisposing PVG allele A) LOD plot of chromosome 6 
shows linkage for disease onset in PVGxF1 but not in F1xPVG rats (peak at 131 Mb, indicated by *)  B) 
The same QTL shows linkage in DAxF1 but not in F1xDA rats. 
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activation (Study II), although with low expression. We decided to investigate potential 
allele-specific expression of five miRNAs, miR-127, miR-136, miR-431, miR-434 and miR-
541 using reciprocal F1 hybrids. We observed some indication for parent-of-origin dependent 
expression, although not significant. Further exploration in different cells types and at 
different ages could provide more information as to where and when imprinting of these 
miRNAs is set.  
 
 
 
 
 
 
 
4.3 Study III - miRNAs as post-transcriptional regulators of EAE 
In addition to genetic and epigenetic regulation of transcription, miRNAs have during the last 
20 years been proven to have a great impact on shaping the transcriptome and ultimate 
phenotype. Prior to the onset of EAE, at day 7 post MOG-EAE induction, an immune 
activation is ongoing in the lymph nodes of both DA and PVG rats. However, this activation 
will only result in subsequent immune cell migration and infiltration into the CNS in the DA 
rats. There is no difference in immune cell populations at this early stage
244
; instead the 
difference between the two strains relies on the quality of the immune response. By 
determining all miRNAs that differ between the two strains at this time point we were able to 
identify a miRNA profile that could be responsible for the pathogenic immune activation. 
Using NGS (Illumina) we could quantify a total of 329 miRNAs in the lymph nodes of DA 
and PVG rats. Forty-three of these miRNA were differentially expressed between the two 
strains. Most of the differentially expressed miRNAs were more highly expressed in the 
EAE-susceptible DA strain. Some of the miRNAs were highly abundant whereas others were 
expressed at very low levels. The latter are likely to be less important for the abundant cell 
types such as CD4
+
 T cells
244
, but could be specific for less prominent cell types. We further 
investigated miRNA expression kinetics and the cellular source for some of the miRNAs to 
get a better understanding of how miRNAs could be regulated during EAE. We observed that 
Figure 12: Dlk1 transgenic mice 
(tg), producing a double dose of 
Dlk1, presented with less severe 
EAE compared to wild type 
littermate controls (wt).   
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some miRNAs are consistently more highly expressed in DA, whereas other miRNAs display 
changes at day 7 only. The cellular source also differed between miRNAs as some (e.g. miR-
181a and miR-128) were predominantly expressed in T cells, and others (e.g. miR-199a-3p 
and miR-223) were rather exclusively expressed in non-lymphocyte cell populations. We 
could thus illustrate genetically controlled and cell-specific miRNA profiles that regulate 
development of pathogenic immune responses.  
 
To understand the functional implication of this miRNA profile one needs to identify the 
potential genes that the miRNAs regulate. For this purpose we used a combination of in silico 
target prediction and known mRNA expression levels in day 7 lymph nodes
211
. By only 
focusing on those genes that were differentially expressed in opposing manners in the lymph 
nodes we were more likely to find lymph node-specific mRNAs that are regulated during 
immune activation. Using this approach we identified 109 target genes potentially regulated 
by the miRNAs with higher expression in the DA strain, and 54 target genes of the miRNA 
with higher expression in the PVG strain. Three of the targets for miR-181a were confirmed 
using in vitro validation experiments, showing that the combination of target prediction tools 
and whole genome expression data can be used to establish targets of miRNAs. By 
preforming pathway analysis we could further explain how differentially expressed miRNAs 
could potentially regulate different pathways of importance during immune activation in the 
EAE-susceptible and the EAE-resistant rats.  
  
4.4 Study IV - Establishing circulating miRNAs as biomarkers of MS 
The establishment of miRNAs as biomarkers of MS is currently focused on the identification 
of miRNA in the circulation
152,154,155,245
. Such circulating extracellular miRNAs are 
advantageous candidates for disease biomarkers as they have been found to be remarkably 
stable, even during harsh treatments such as variations in temperature and multiple freeze-
thaw cycles
246
. In addition, they can be fairly easily detected in most biofluids
68
. In Study IV 
we aimed to profile miRNAs in the CSF of MS patients and controls with the prospect of 
identifying novel biomarkers of disease. Using TLDA cards we were able to detect a total of 
88 miRNA is CSF pools of CIS, MS, other neurological disorder (OND) and inflammatory 
OND (iOND) patients.  
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Figure 13: A) Levels of circulating miR-150 in CSF is significantly different between MS and controls. B) 
MiR-150 levels are higher in CIS patients that converted to MS (CIS-MS) compare to those not yet converted. 
  
Based on detection we selected 15 miRNAs for further validation in a larger independent 
sample cohort comprising 142 individuals (31-43 patients per group). We could detect 
significant differences in miRNA levels between MS and controls for two miRNAs, miR-145 
and miR-150. MiR-145 was of particular interest as it has previously been identified as a 
biofluid marker for MS in both serum and plasma
154,245
 as well as in circulating PBMC
154,247
. 
MiR-150 has also been associated with MS as a marker in T-cells and PBMCs
248,249
. The 
utilized patient cohort is similar in size to that of other miRNA biomarker studies, but given 
the rather uniquely large biobank established at the Karolinska University Hospital, we 
sought to further investigate miR-145 and miR-150 in a much larger cohort (n=430). In this 
large sample cohort we were able to confirm differential levels of miR-150, but not of miR-
145, thus demonstrating a necessity for validation in large cohorts. In our study we 
determined miR-150 levels to be significantly different between MS and both control groups, 
as well as between CIS and OND (Figure 13A). When subdividing CIS patients we also 
observed higher levels of miR-150 in those individuals that later converted to MS compared 
to those not yet converted in follow-up (Figure 13B), indicating a potential use of miR-150 to 
facilitate earlier diagnosis.  
 
 
To evaluate the potential of miR-150 to act as a biomarker distinguishing MS and OND we 
constructed a Receiver Operating Characteristic (ROC) curve. An ROC curve is used to 
evaluate diagnostic accuracy of a biomarker, visualizing true-positive rate (sensitivity) and 
false-positive rate (1 – specificity). Area under the ROC curve (AUC) can range from 0.5 (no 
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Figure 14: Levels of circulating miR-150 in MS correlates with several immunological disease 
parameters such as A) the number of cells in the CSF and B) levels of biomarker CXCL13 in the CSF. 
  
predictive ability) to 1 (perfect discrimination/accuracy)
250
. AUC for miR-150 was 0.74, 
indicating that miR-150 could differentiate MS and controls providing optimal cut-off at 2.84 
with a specificity of 88% and sensitivity of 51%.  
 
Circulating miRNAs in the CSF likely reflect events in the target organ, the CNS.  In MS the 
pathogenic events are mainly represented by inflammation and demyelination. By 
investigating the relationship between miR-150 levels and established markers of disease we 
observed a positive correlation with several immune parameters. Levels of miR-150 
correlated with the amount of cells in the CSF (Figure 14) and with the IgG index, both 
factors indicating immunopathology in the CNS. We also measured higher levels of miR-150 
in OCB-positive patients. In further support of the immune-association of miR-150, we 
observed a positive correlation of miR-150 with the recognized immune biomarkers, 
CXCL13 (Figure 14) and MMP9. Conversely, we did not determine any relationship between 
levels of miR-150 and markers of neurodegeneration such as EDSS score, number of lesions 
or levels of NFL in the CSF.  
 
 
 
 
 
 
 
 
To facilitate the use of miR-150 as a biomarker in a clinical setting we investigated the 
potential of using a ‘miRNA pair’ to discriminate patients and controls, where the ratio of 
two miRNAs serves as a marker and thereby bypassed the need for spike-in controls. By 
comparing all possible miRNA pairs among the 15 tested miRNAs we concluded that the 
ratio of miR-150 and miR-204 best served this purpose. The miR-150/miR-204 ratio was 
found to have better potential to serve as biomarker (AUC 0.80), compared to miR-150 alone.   
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Figure 15: Studies of this thesis demonstrate that both epigenetic factors and miRNAs can act as modulators 
of the information transmitted from the genetic code to the functional transcriptome (Study II and III). In 
addition, variations in the genetic information could potentially influence translation in a direct manner (Study 
I). Furthermore, dysregulated miRNAs have a great potential to act as biomarkers of disease (Study IV).   
  
5 DISCUSSION AND CONCUSIONS 
 
5.1 Epigenetics and miRNAs as modulators and mediators of 
neuroinflammation  
The genetic diversity of humans and model animals has long been used to investigate the 
contribution of genetic regulation on disease susceptibility and severity. However, there is an 
ever-growing body of evidence for epigenetics and miRNAs being involved in shaping the 
transcriptome in pre- and post-transcriptional manners, during both physiological and 
pathological conditions. Epigenetics and miRNAs are likely to both modulate and mediate 
genetic information based on extrinsic and intrinsic signals. My studies have investigated the 
contribution of epigenetics to the heritability of experimental neuroinflammation both as 
mediators (Study I) and modulators (Study II). Furthermore, I have investigated miRNAs 
both as potential regulators of EAE susceptibility (Study III) and as biomarkers of MS (Study 
IV) (Figure 15).  
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5.2  Kdm3a is not a master regulator of EAE  
We hypothesized that Kdm3a acts as a ‘master regulator’ mediating diverse immunological 
phenotypes through epigenetic modifications (Study I). Given its role as a histone modifier, 
Kdm3a could epigenetically mediate regulation by altering the chromatin state. Kdm3a, a 
member of the Jumonji C domain-containing family proteins, is known to catalyze the 
reversal of H3K9 mono- and di- methylation. H3K9 methylation, which is associated with 
transcriptional repression
14,251
, has been shown to be essential for T and B cell 
development
252
 as well as being important in the regulation of effector molecules such as IL-
2
253
. Owing to this potential role of Kdm3a we were surprised to observe that complete 
removal of the gene did not result in any observed impact on the immune system or on EAE 
pathogenesis in mice. This could indicate that H3K9 methylation is of less importance in the 
context of EAE. Alternatively, this negative finding might just result from a difference 
between model species or that Kdm3a has important roles in the immune system other than 
those investigated. Another possibility is that the use of a full knockout results in the 
activation of compensatory mechanisms. Using a conditional knockout of Kdm3a, depleting 
Kdm3a in a specific cell type, for instance in macrophages, might have resulted in an effect 
on EAE pathogenesis. However, a conditional Kdm3a knockout mouse was not available at 
that time. Despite the disappointing results in the mouse model, Kdm3a could still be a 
candidate gene underlying the observed effects in rats. Historically, mouse have been the 
models of choice to study gene function, as tools for genetic manipulation in vivo were 
readily available in mice and gene targeting in rats was proven very difficult
254
. However, 
with recent advancements in genetic engineering, especially with the CRISPR/Cas9 system, it 
is now possible to modify the Kdm3a SNP in the DA strain. This would enable investigation 
of both nucleotide variations on the same genetic background. Genetic engineering could also 
be utilized to investigate the contribution of the other genes and regulatory regions within the 
disease promoting QTL.  
 
Although Kdm3a is not regulating EAE through epigenetic mechanisms in mice, we found a 
synonymous coding SNP in the rat Kdm3a gene that may potentially directly regulate 
translation of the gene. The seemingly silent SNP had dramatic effects on PCR efficiency as a 
result of altered cDNA folding, demonstrating the importance of examining PCR parameters 
and sequence differences between sample subjects. The finding that a synonymous SNP can 
affect mRNA quantification and RNA folding has previously been indicated
255,256
, yet 
synonymous SNPs are rarely accounted for in studies of gene expression. In almost all of the 
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experiments of translation potential we observed a lower Renilla Luciferase activity with the 
DA Kdm3a SNP, indicating that the SNP may affect translation. Experiments in vitro all 
focused on the 181bp amplicon harboring the SNP, thus whether this also occurs for the full-
length mRNA in vivo remains uncertain. However, there is some evidence for synonymous 
SNPs altering protein translation
255
 and Shape Probability Shift analysis suggests that the 
SNP in Kdm3a has a significant impact on RNA folding.  
 
This study sheds more light on the complexity of genomic variations. In the age of genomics 
and genome-wide association studies (GWAS) there is an ever-growing number of SNPs 
identified and associated with complex diseases. Initially, attention was given to SNPs that 
affect protein structure, and synonymous SNPs have largely been ignored. Here we 
demonstrate that by disregarding such variation, important biologically relevant aspects could 
be overlooked, such as in our case the implication of silent SNPs on the downstream nucleic 
acid folding and translation. Additionally, majority of the identified genetic variations that 
associate with diseases are located in intergenic regions. Apart from their obvious impact on 
regulatory elements their influence on other transcribed RNA products are yet to be 
discovered. Given that we now know that most of the genome is being transcribed, such 
mechanisms may be of more importance than originally believed.  
 
5.3 Evidence for parent-of-origin effects in EAE 
Another mechanism of epigenetically mediated regulation of the transcriptome is parent-of-
origin effects.  In Study II we show that there is a large contribution of such effects in EAE 
etiology. Using a reciprocal backcross strategy we could demonstrate that 37-54% of the 
identified disease-predisposing loci depend on parental transmission and that accounting for 
parental transmission could further explain the disease variance by 2-4 fold. The identified 
preferential maternal pattern of disease inheritance has also been observed in MS
134-136
. 
Taken together we clearly demonstrate that accounting for parental origin can help to 
discover more risk loci and can further explain more of the previously unknown genetic 
regulation of underlying EAE. Furthermore, the fact that we observe EAE susceptibility 
alleles being transmitted from the PVG suggests that both strains contain both risk genes and 
protective genes and that it is the balance of these that ultimately determines susceptibility.  
The significant impact of parent-of-origin effects implicates epigenetic mechanisms (e.g. 
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DNA methylation and non-coding RNAs, that commonly control imprinting) modulating the 
genetic information in autoimmune inflammation.  
 
Several of the parent-of-origin QTLs overlap with known imprinted genes, some of which 
with known importance for the immune system. One of these, underlying the maternally 
transmitted QTL on chromosome 2, is the maternally expressed Igf2r
257
 gene. Igf2r is known 
to be important for T cell activation
258
 and for regulatory T 
259
 and B cell
260
 function. The 
paternally transmitted locus on chromosome 6 overlaps with the imprinted Dlk1-Dio3 cluster 
containing paternally expressed genes. Using a transgenic model we could identify Dlk1 as a 
novel candidate gene for EAE, predisposing for more severe disease when paternally 
transmitted in rats. Dlk1 is an atypical Notch ligand, which is suggested to inhibit signaling 
through the Notch pathway
261,262
. Notch signaling has previously been implicated in the 
pathogenesis of MS and EAE
263,264
, where the signaling pathway is known to regulate key 
players in the immune response
265-267
, was well as oligodendrocytes
268
, thereby potentially 
affecting both demyelination and remyelination processes. In addition to coding genes, this 
imprinted region also contains a large cluster of miRNAs, all of which are maternally 
expressed
241
. Two of these, miR-127 and miR-136, are important during development where 
they target the Rlt1 gene on the paternally inherited allele, thereby silencing it
269
. 
Furthermore, several miRNAs in this cluster have been associated with human 
malignancies
270
, and identified as differentially expressed in EAE (Study III). The latter 
indicates a role of imprinted miRNAs in immune cell regulation and in experimental 
neuroinflammation.  
 
This is the first study to demonstrate the contribution of parent-of-origin effects in regulating 
susceptibility to EAE in rats. By controlling for the environment we exclude external 
contribution to the observed effects, implicating that risk factors of EAE development can be 
modulated my epigenetic mechanisms. Our findings also suggest that accounting for parent-
of-origin effects in human genetic studies would likely result in identifying additional risk 
genes and explaining more of the heritability of complex diseases.  
 
5.4 MiRNAs as regulators of pathogenic immune response 
It is now well established that miRNAs play an important role in regulating biological 
processes, including the immune system. Studies of miRNA regulation during EAE have 
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primarily been focusing on the role of miR-155
58,203,204,271
 and miRNA as regulators of Th1 
and Th17 cells
197-200
. In Study III we established a miRNA profile regulating susceptibility to 
develop EAE, determining both miRNAs that mediate a pathogenic immune phenotype and 
the potential target genes modulated by the differentially expressed miRNAs (Figure 16A). 
The miRNA profile demonstrated that the majority of the miRNAs had higher expression in 
the susceptible strain. Together with the different expression kinetics and cellular source of 
miRNA expression, we conclude that miRNA regulation of EAE susceptibility is likely a 
result of both miRNAs promoting disease and miRNAs expressed to regulate ongoing 
inflammation.  
 
Even though we observed quite a large number of differentially expressed miRNAs, the fold-
change between the strains was modest. This is not surprising as miRNA dysregulation in 
diseases, including MS, is rarely that extensive
247,272
. This might be due to the feedback 
mechanisms that regulate miRNA levels. Given that each miRNA can regulate a vast number 
of genes, it is not surprising that their expression is under tight regulation. The feedback loops 
regulating miRNA levels further demonstrate the role of miRNAs in fine-tuning biological 
processes
273
. One of the most studied miRNA in inflammation, miR-146a, which was higher 
expressed in DA rats, is an example of this. A negative feedback loop is generated as miR-
146a, which is upregulated by immune activation, downregulates factors of the immune 
signaling pathway and thereby controls the immune activation
59
. In view of the central role 
that miRNAs have in fine-tuning the immune response it is not unexpected that miRNA 
dysregulation can disrupt the intricate feedback system and ultimately cause disease (Figure 
16 B). Given the high conservation of miRNAs between species and possibly shared 
functions in MS and EAE pathogenesis
197
, miRNAs identified in EAE susceptibility might 
also be important in the early stages of MS. In animal models they play a crucial role during 
this early time-point, prior to diagnosis, which is not possible to study in human disease. 
 
To understand how the alterations in miRNA expression can lead to disease we investigated 
the functions and pathways regulated by targets of the differentially expressed miRNAs. By 
integrating expression analysis with miRNA target predictions we identified miRNA-
regulated genes important for EAE susceptibility. It is now shown that the binding of miRNA 
the 3’UTR of mRNA primarily results in mRNA deamination and decay274, justifying the 
pursuit for miRNA targets with inverse correlated expression. However, translational 
repression occurs without change in mRNA levels
275
 and these targets will therefore be 
overlooked. By demonstrating a direct interaction of one miRNA with three of its predicted 
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Figure 16: A) Illustration of how miRNA can mediate and modulate the transmission of information. 
B) MiRNAs work in feedback systems to fine-tune biological processes. Dysregulation of miRNA 
levels can both reduce negative control regulation and increase positive control regulation, thereby 
further enhancing the phenotype.  
  
target genes we further demonstrate that the targets we identified are likely to be true. Several 
pathways and functions were enriched in the list of miRNA targets. Targets of miRNAs with 
higher expression in the susceptible DA strain were involved in functions related to the 
migration and homing of immune cells. The potential for the autoreactive immune cells to 
migrate and infiltrate the CNS is one of the hallmarks of MS and EAE. The miRNA were 
shown to target several important chemokines and their receptors, such as CXCL13, 
CCL3L1, CXCR3, all of which are have previously been associated with MS and 
EAE
172,276,277
.  
 
 
 
 
 
Although the list of miRNA downregulated genes in the PVG was shorter, pathway analysis 
was still informative and suggested miRNA associated regulation of B lymphocyte 
differentiation and apoptosis. The first is mainly regulated my miR-150, which is known to 
regulate T and B cell differentiation
52,64
. The levels of miR-150 are reduced as the 
lymphocytes differentiate, possibly indicating that PVG produces less fully differentiated 
effector cells. Furthermore, the amount of autoreactive cells in the PVG could be controlled 
by miRNA-mediated regulation of apoptosis. Taken together, the miRNAs and their targets 
give new insight into the complicated regulation that occurs during immune activation and 
that altered expression of miRNAs can contribute to EAE susceptibility. The direct 
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mechanism through which the individual miRNAs influence the immune systems deserves 
further investigation.  
 
5.5 Circulating miRNAs as biomarkers of neuroinflammation 
For complex diseases, where the cause is unknown, there is a high demand for good 
biomarkers. Biomarkers of disease are of extra relevance in MS given the inaccessibility of 
the target organ. A large number of molecules identified in blood and CSF of MS patients has 
been proposed as biomarkers
278
, although few have been extensively evaluated in a larger 
sample cohort
278
. Circulating miRNAs as biomarkers in the CSF have primarily been 
identified in neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases72,279. 
To date, only one study has investigated circulating miRNAs in the CSF of MS patients and 
controls
155
. In pooled CSF samples from MS patients and controls we could reliably detect 88 
miRNAs. Detected miRNAs displayed poor overlap with those miRNAs detected in the study 
by Haghikia et al, but we observed a substantial overlap (63%) with miRNAs detected in 
active and inactive lesions
148
, indicating that our miRNA profile mirrors events happening in 
the CNS during MS.  
 
In a uniquely large sample cohort we demonstrated miR-150 as a putative new biomarker for 
MS. MiR-150 has previously been found downregulated in PBCMs and T cells in MS 
compared to healthy controls
248,249
. Levels of miR-150 in the CSF correlated with 
immunological parameters, indicating that miR-150 is either released from infiltrating 
immune cells or by CNS resident cells in an attempt to downregulate the inflammation. Both 
monocytes and lymphocytes release miR-150. MiR-150 released by monocytes promote 
endothelial cells migration and angiogenesis
280,281
 and miR-150 secreted by B cells
282
 could 
potentially be taken up by CD8
+
 T cells
283
. More and more evidence suggests an important 
role of B cells in the pathophysiology of MS, an observation further supported by the 
therapeutic potential of B cell-depleting anti-CD20 monoclonal antibodies (Rituximab) in 
RRMS
102
. We determined positive association of miR-150 to OCBs, IgG index and CXCL13, 
all of which are markers of B cell immunopathology
96,101,284
. This indicates that miR-150 may 
be released from infiltrating B cells or from other cells that impact on B cell function. These 
are as yet speculations and further investigation of the role of miR-150 in MS is warranted. 
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Extracellular miRNAs in biofluids have a great potential as biomarkers due to their stability 
and accessibility. As opposed to protein biomarkers, several miRNAs can be detected in a 
single isolation procedure from a fairly small sample volume. To aid clinical implementation 
we reveal how challenges with miRNA normalization in circulation can be circumvented 
with the use of ‘miRNA pairs’ as diagnostic markers. The miR-150/miR-204 ratio reflects 
variations in both miRNAs and actually provided a better marker than miR-150 alone.  
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6 CONCLUDING REMARKS AND POINTS OF 
PERSPECTIVE 
 
Diseases such as MS are challenging to study as they arise from a complex interaction of 
numerous genes and environmental factors. The fact that most of the mechanisms underlying 
this interaction remain undiscovered, and that the pathogenic triggers are likely to vary 
among patients, further adds to the complexity. The epigenome integrates signals from the 
genome and the environment, thereby shaping the transcriptome. Through continuous 
exploration of epigenetic mechanisms and miRNAs involved in MS etiology, we are likely to 
unravel more of these underlying mechanisms.  
 
In the first study we were unable to demonstrate the potential of the histone demethylase 
Kdm3a in regulating autoimmunity in mice. Histone modifications have been implicated in 
both MS and EAE, but the histone code is comprised of a multitude of modifications 
regulated by a large number of enzymes, and not all of them are likely to be important in 
immune system regulation. However, whether Kdm3a is equally dispensable in rat EAE has 
yet to be investigated. With novel techniques of gene targeting, similar investigations in rats 
are now possible. 
 
During the past decades a large focus has been on identifying risk factors for MS such as 
genetic variations and environmental influences. Genetic studies have largely focused on 
factors that follow Mendelian inheritance and which affect either regulatory regions, and 
hence levels of gene transcription, or protein structure. My work demonstrates the importance 
of extending these investigations to account for ‘silent’ variations and miRNAs that 
eventually impact the proteome. Additionally, my work highlights a necessity to consider 
non-Mendelian inheritance and the fact that, among others, risk genes will also be modulated 
by epigenetic mechanisms. 
 
Study I demonstrated how a seemingly silent SNP can affect the nucleotide secondary 
structure and potentially protein translation. This finding implicates a new impact of the 
previously largely overlooked synonymous SNPs. Although they do not change the protein 
product, they may change the rate at which they are translated. Assumptions of candidate 
genes underlying QTLs generally include identification of non-synonymous SNPs that may 
46 
 
result in altered proteins. However, in the light of our findings synonymous SNPs may also 
be informative, and should be investigated accordingly. Furthermore, although it was 
previously known that SNPs can alter the secondary structure, they are not accounted for 
when designing experiments to measure RNA expression. Tools should be developed so that 
SNP effects on RNA secondary structure can be modulated and interpreted. 
 
In Study II we demonstrate significant parent-of-origin effects in inheritance of EAE, 
corroborating similar suggested effects in MS, which were questioned due to potential 
confounding factors in epidemiological studies. By accounting for parent-of-origin effects, 
novel risk genes/regions are likely to be discovered. The identification of parent-of-origin 
regulated loci may reflect genomic areas that are open to regulation by the environment, and 
so present an opportunity to further explore gene-environment interactions. Although 
identification of candidate imprinted genes underlying the parent-of-origin dependent EAE 
QTLs proved to be challenging, ongoing efforts to identify genome-wide imprinted genes in 
relevant immune cells using RNA sequencing in reciprocal F1 hybrids is ongoing. These 
experiments will not only identify the genes underlying the parent-of-origin EAE QTLs, but 
also address the impact and functions of imprinting in immune cells.  
 
MiRNAs are known to be dysregulated in most diseases and the role of a few miRNAs has 
been demonstrated in EAE. The findings of Study III demonstrate that in the context of 
complex diseases, several miRNAs are more likely to act together in a fine-tuning manner 
rather than a single or a few miRNAs exerting dramatic effects. The miRNA profile 
identified is different from that reported in other studies, as it demonstrates miRNAs that are 
differentially expressed between pathogenic and non-pathogenic immune activation states, as 
opposed to differences been disease and healthy states. We identified several miRNAs with 
known immune functions, and many with less well-documented functions. Further studies are 
required to investigate their roles in regulating autoimmunity. Functional miRNA studies 
generally investigate the role of a single miRNA. However, our study demonstrates that 
miRNAs are likely both disease-promoting (pathogenic miRNAs) and disease-protective 
(regulatory miRNAs). Future functional studies could therefore be more informative if the net 
effect of several miRNAs is investigated. Targeting or over-expressing several miRNAs 
could also provide new therapeutic options in the future, especially considering development 
in small RNA interventions. 
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There is an ever-pressing need for surrogate markers of complex disease that can facilitate 
early diagnosis, better stratify patients in subgroups, and that can predict prognosis and 
treatment outcome. Study IV demonstrates the potential of circulating miRNAs in the CSF to 
serve this purpose. However, we clearly show that larger cohorts than those commonly used 
are required to fully evaluate the potential for each identified marker. Furthermore, given the 
heterogeneity of complex diseases it is likely that a panel of biomarkers is necessary to reflect 
different disease variations. As several miRNAs can be detected in a single isolation protocol, 
they could present a great feasibility in a clinical setting. In the case of miR-150, future 
investigation should test its potential as a biomarker of disease in other body compartments, 
which are more easily accessible, and its potential to serve as a marker for treatment 
response.   
 
Ultimately, the goal in MS research is to understand the cause and the underlying disease 
mechanisms. Through understanding of the genetic factors, epigenetic mediators and 
modulators and how the environment interacts with these factors we can improve prediction 
and hopefully prevent and cure disease. The reversibility of epigenetic mechanisms makes 
them great targets for future development of ‘epigenetic medicine’.  
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